Tissue advanced glycation end product deposition after kidney transplantation

Nephron - Clinical Practice

Volumn 124, Issue 1-2, 2013, Pages 54-59

  Crowley, Lisa E ^a   Johnson, Catherine P ^a   McIntyre, Natasha ^a   Fluck, Richard J ^a   McIntyre, Christopher W ^b   Taal, Maarten W ^a   Leung, Janson C H ^a  

^a ROYAL DERBY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Advanced glycation end products; Cardiovascular risk; Chronic kidney disease; Transplantation

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

ADULT; ARTICLE; AUTOFLUORESCENCE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; DIALYSIS; FEMALE; FLUORESCENCE ANALYSIS; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GROUPS BY AGE; HEMODIALYSIS; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SEX DIFFERENCE; SKIN AUTOFLUORESCENCE; CARDIOVASCULAR RISK; CONTROLLED STUDY; ETHNICITY; FOLLOW UP; HEMODIALYSIS PATIENT; PERITONEAL DIALYSIS; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

ADVANCED CARDIAC LIFE SUPPORT; AGED; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SKIN;

EID: 84885553287     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000355692     Document Type: Article

References (25)

1. Jardine AG, et al: Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 2011; 378: 1419-1427.
2. Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995; 46: 223-234.
3. Miyata T, et al: Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 1998; 53: 416-422.
4. Meerwaldt R, et al: Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007; 30: 107-112.
5. Smit AJ, et al: Advanced glycation endproducts in chronic heart failure. Ann NY Acad Sci 2008; 1126: 225-230.
6. Aronson D: Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 2003; 21: 3-12.
7. Semba RD, et al: Serum carboxymethyllysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens 2009; 22: 74-79.
8. Di Micco L, et al: Daily dialysis reduces pulse wave velocity in chronic hemodialysis patients. Hypertens Res 2012; 35: 518-522.
9. Peppa M, Raptis SA: Advanced glycation end products and cardiovascular disease. Curr Diabetes Rev 2008; 4: 92-100.
10. Bansal S, et al: Advanced glycation end products enhance reactive oxygen and nitrogen species generation in neutrophils in vitro. Mol Cell Biochem 2012; 361: 289-296.
11. Basta G, Schmidt AM, De Caterina R: Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63: 582-592.
12. Godfrey AR: Impact of glucose levels on advanced glycation end products in hemodialysis. Hemodial Int 2007; 11: 278-285.
13. Makita Z, et al: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-842.
14. McIntyre NJ, et al: Tissue-advanced glycation end product concentration in dialysis patients. Clin J Am Soc Nephrol 2010; 5: 51-55.
15. Meerwaldt R, et al: Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3687-3693.
16. Hartog JW, et al: Advanced glycation end products in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction. Am J Kidney Dis 2004; 43: 966-975.
17. Hartog JW, et al: Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann NY Acad Sci 2005; 1043: 299-307.
18. McIntyre NJ, et al: Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. Clin J Am Soc Nephrol 2011; 6: 2356-2363.
19. Meerwaldt R, et al: Simple noninvasive measurement of skin autofluorescence. Ann NY Acad Sci 2005; 1043: 290-298.
20. Noordzij MJ, et al: Dermal factors influencing measurement of skin autofluorescence. Diabetes Technol Ther 2011; 13: 165-170.
21. Meerwaldt R, et al: Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia 2005; 48: 1637-1644.
22. Monami M, et al: Skin autofluorescence in type 2 diabetes: beyond blood glucose. Diabetes Res Clin Pract 2008; 79: 56-60.
23. Koetsier M, et al: Reference values of skin autofluorescence. Diabetes Technol Ther 2010; 12: 399-403.
24. Hartog JW, et al: Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients. Nephrol Dial Transplant 2006; 21: 2263-2269.
25. Hartog JW, et al: Skin-autofluorescence is an independent predictor of graft loss in renal transplant recipients. Transplantation 2009; 87: 1069-1077.